title: Helicobacter pylori eradication does not change circulating insulin-like growth factor 1 and insulin-like growth factor binding protein 3 levels in patients with and without precancerous gastric lesions.
abstract: BACKGROUND
  Circulating insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-3 levels in the serum of Helicobacter pylori (H pylori)-infected patients were investigated.
  
  
  METHODS
  The study subjects consisted of 54 patients with H pylori infection, and the control subjects included 27 patients without H pylori infection. There was no statistical difference in the age and sex distributions between the study and control groups. Pretreatment serum levels of IGF-1 and IGFBP-3 were studied in all the subjects, including the healthy controls. H pylori eradication was achieved with a triple drug regimen for 2 weeks, and 1 month after this treatment, the serum levels of IGF-1 and IGFBP-3 were measured. The post-treatment H pylori status by a second gastroscopy, antral histopathology and urea breath testing was tested.
  
  
  RESULTS
  The pretreatment serum levels of IGF-1 and IGFBP-3 of the study and control groups were not found to be different (P > 0.05). H pylori treatment was successful in 42 patients in whom both serum IGF-1 and IGFBP-3 levels decreased with treatment, but the difference was only significant for the serum IGF-1 levels (P: 0.04). There was no change in the serum levels of IGF-1 and IGFBP-3 in the 27 patients with precancereous gastric lesions before and after successful H pylori eradication.
  
  
  CONCLUSIONS
  No supporting evidence of a major interaction between H pylori infection itself and H pylori-associated premalignant lesions with circulating IGFBP-3 levels could be shown. Nevertheless, successful eradication of this microorganism led to a statistically significant decrease in serum IGF-1 levels.
authors.affiliation: Departments of Internal Medicine (YU, HS, SI), Gastroenterology Clinics, Pathology (BGD) and Biostatistics (FIK), Zonguldak Karaelmas University Hospital, Zonguldak, Turkey; and Clinics of General Surgery (FAK), Zonguldak State Hospital, Zonguldak, Turkey.
authors.forename: Yücel
authors.initials: Y
authors.lastname: Ustundag
authors.forename: Hatice
authors.initials: H
authors.lastname: Sahin
authors.forename: Sevil
authors.initials: S
authors.lastname: İlikhan
authors.forename: Banu Gun
authors.initials: BG
authors.lastname: Dogan
authors.forename: Firuzan
authors.initials: F
authors.lastname: Kokturk
authors.forename: Fatih
authors.initials: F
authors.lastname: Kar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D004359:Drug Therapy, Combination; D005260:Female; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000097:blood / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011230:Precancerous Conditions / Q000097:blood* / Q000473:pathology; D011706:Pyloric Antrum / Q000378:metabolism / Q000473:pathology; D013274:Stomach Neoplasms / Q000097:blood* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I